Loss-of-Function Genetic Screens to Find Genes Regulating Cell Responses and Identify Potential Drug Targets.

被引：0
|
作者：
Diehl, P. [1 ]
Tedesco, D. [1 ]
Bonneau, K. [1 ]
Makhanov, M. [1 ]
Deng, D. [1 ]
Hyder, K. [1 ]
Sun, P. [2 ]
Chenchik, A. A. [1 ]
机构：
[1] Cellecta Inc, Mountain View, CA USA
[2] Scripps Res Inst, La Jolla, CA 92037 USA
来源：
MOLECULAR BIOLOGY OF THE CELL | 2014年 / 25卷
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
P1621
引用
收藏
页数：1
相关论文
共 14 条
  • [1] Gain and loss-of-function screens identify targets with improved AAV production
    Reid, A. C.
    Grafton, F.
    Leveque-Eichhorn, L.
    Brim, J.
    Ukani, I.
    Fisher, K.
    Hoerer, M.
    Mandegar, M. A.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A159 - A159
  • [2] Evaluating drug targets through human loss-of-function genetic variation
    Eric Vallabh Minikel
    Konrad J. Karczewski
    Hilary C. Martin
    Beryl B. Cummings
    Nicola Whiffin
    Daniel Rhodes
    Jessica Alföldi
    Richard C. Trembath
    David A. van Heel
    Mark J. Daly
    Stuart L. Schreiber
    Daniel G. MacArthur
    Nature, 2020, 581 : 459 - 464
  • [3] Evaluating drug targets through human loss-of-function genetic variation
    Minikel, Eric Vallabh
    Karczewski, Konrad J.
    Martin, Hilary C.
    Cummings, Beryl B.
    Whiffin, Nicola
    Rhodes, Daniel
    Alfoldi, Jessica
    Trembath, Richard C.
    van Heel, David A.
    Daly, Mark J.
    Schreiber, Stuart L.
    MacArthur, Daniel G.
    NATURE, 2020, 581 (7809) : 459 - +
  • [4] Gain and Loss-of-function screens identify targets with >10-fold improvement in AAV production
    Reid, C. A.
    Grafton, F.
    Leveque-Eichhorn, L.
    Griffiths, H.
    Mandegar, M. A.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A98 - A98
  • [5] Author Correction: Evaluating drug targets through human loss-of-function genetic variation
    Eric Vallabh Minikel
    Konrad J. Karczewski
    Hilary C. Martin
    Beryl B. Cummings
    Nicola Whiffin
    Daniel Rhodes
    Jessica Alföldi
    Richard C. Trembath
    David A. van Heel
    Mark J. Daly
    Stuart L. Schreiber
    Daniel G. MacArthur
    Nature, 2021, 590 : E56 - E56
  • [6] Evaluating drug targets through human loss-of-function genetic variation (vol 581, pg 459, 2020)
    Minikel, Eric Vallabh
    Karczewski, Konrad J.
    Martin, Hilary C.
    Cummings, Beryl B.
    Whiffin, Nicola
    Rhodes, Daniel
    Alfoldi, Jessica
    Trembath, Richard C.
    van Heel, David A.
    Daly, Mark J.
    Schreiber, Stuart L.
    MacArthur, Daniel G.
    NATURE, 2021, 590 (7846) : E56 - E56
  • [7] Loss-of-function and gain-of-function genetic screens identify potential biomarkers and combination partners for the highly selective allosteric PI3Kd inhibitor roginolisib (IOA-244)
    Tarantelli, C.
    Sartori, G.
    Spriano, F.
    Civanelli, E.
    Cascione, L.
    Rinaldi, A.
    Niewola-Staszkowska, K.
    Lahn, M.
    Napoli, S.
    Di Conza, G.
    Bertoni, F.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S15 - S15
  • [8] A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors
    Rogers, Laura M.
    Wang, Zhaoming
    Mott, Sarah L.
    Dupuy, Adam J.
    Weiner, George J.
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (09) : 1206 - 1214
  • [9] Using RNAi-based genetic screens to identify essential genes involved in pancreatic beta-cell function
    Antinozzi, PA
    Rothman, JE
    DIABETES, 2004, 53 : A31 - A31
  • [10] Loss-of-function screens using haploid KBM7 and HAP1 cells to identify mechanisms of anti-cancer drug resistance
    Gerhards, Nora M.
    Guyader, Charlotte
    Blomen, Vincent A.
    Kucukosmanoglu, Asli
    van Tellingen, Olaf
    Vis, Daniel J.
    Wessels, Lodewyk F.
    Brummelkamp, Thijn R.
    Borst, Piet
    Rottenberg, Sven
    CANCER RESEARCH, 2015, 75
12